Parsippany-based Teva Pharmaceutical announced changes to its leadership team on Thursday.
Executive Vice President, North America Commercial, Sven Dethlefs will leave Teva on Nov. 17, and Christine “Chris” Fox, who most recently served as global president, gene therapies, at Novartis, will be the new head of Teva’s U.S. Commercial Business.
“On behalf of the Teva board of directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company,” Richard Francis, Teva’s CEO and president, said. “I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a heralded pharmaceutical executive with extensive experience growing and overseeing complex business units and regional operations throughout the world. I have every confidence that Chris will bring great strength to Teva and be pivotal to our success.”
Fox brings more than 30 years of health care industry experience with leadership roles in sales, marketing and commercial operations, responsible for teams ranging from 2,500-plus associates to small, nimble consulting teams.
Fox comes to Teva from her role at Novartis Gene Therapies, where she started as president in December 2021. Prior to this role, Fox was vice president and general manager for the bone, cardiometabolic and nephrology business for Amgen. She also served as the general manager of the company’s U.K. and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda and several startups.
